Patents Assigned to FUND OF THE TEL AVIV MEDICAL CENTER
  • CD14 AND PEPTIDES THEREOF FOR PROTECTION OF CELLS AGAINST CELL DEATH
    Publication number: 20100331239
    Abstract: Provided is a method of using soluble CD14 or peptides derived therefrom for protecting cells from death, specifically from apoptotic cell death. Further provided are compositions including CD14 or CD14 peptides and methods for protecting cells, in particular lymphocytes, from apoptotic cell death. The compositions and methods are relevant, in particular, for the treatment of various immune deficiencies associated, for example, with cell transplantation procedures, autoimmune diseases and infectious diseases such as HIV.
    Type: Application
    Filed: January 29, 2009
    Publication date: December 30, 2010
    Applicants: FUND OF THE TEL AVIV MEDICAL CENTER
    Inventors: Boris Tartakovsky, Elizabeth Naparstek
  • METHODS OF TREATING TUMORS IN IMMUNE-PRIVILEGED SITES
    Publication number: 20100189750
    Abstract: A method of treating cancer in an immune-privileged site of a subject in need thereof is provided. The method comprises systemically administering to an area outside the immune-privileged site of the subject, a therapeutically effective amount of naive, viable cells of a tumor of the subject, the tumor being in the immune-privileged site so as to generate an immune response in the subject, thereby treating the cancer in the immune-privileged site of the subject.
    Type: Application
    Filed: September 11, 2008
    Publication date: July 29, 2010
    Applicants: Yeda Research And Development Co. Ltd., The Medical Research, Infrastructure, and Health Services Fund of the Tel Aviv Medical Center
    Inventors: Ilan Volovitz, Lea Eisenbach, Irun R. Cohen, Zvi Ram, Shimon Slavin
  • METHODS OF TREATING CANCER USING siRNA MOLECULES DIRECTED AGAINST CD24
    Publication number: 20100130587
    Abstract: A method of treating a CD24-related medical condition is disclosed. The method comprises administering to a subject in need thereof at least one siRNA molecule selected from the group consisting of SEQ ID NO: 1 to 4. Pharmaceutical compositions comprising same are also disclosed.
    Type: Application
    Filed: November 13, 2007
    Publication date: May 27, 2010
    Applicant: The Medical Research, Infrastructure, and Health Services Fund of the Tel Aviv Medical Center
    Inventors: Nadir Arber, Eyal Sagiv